News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Recent Advances in Controlled Release, Solubility, and ODT Applications Presented by Catalent Pharma Solutions Expert at CRS Conference



7/11/2012 9:32:56 AM

SOMERSET, NJ, July 11, 2012 — Michael J. Valazza R.Ph., Vice President, Global Modified Release Technologies, Catalent Pharma Solutions, will be presenting on “Recent Advances in Oral Granules and Fixed Dose Tablet technologies, OptiMeltTM Solubility Enhancement Solutions, and Oral Disintegrating Tablet applications,” on Sunday, July 15th from 10:15AM -11:15AM as part of a releasing technology workshop (room 202) at the 39th annual Controlled Release Society Conference. This educational workshop will focus on new advancements in modified controlled release technologies, including novel OSDrC® OptiDoseTM optimized dose delivery technology, solubility enhancement with OptiMeltTM hot melt extrusion, and case studies of Zydis® fast-dissolve applications.

Optimized Products and Better Treatments:

OSDrC® OptiDoseTM optimized dose delivery technology offers the broadest range of controlled release, combination (tablet-within-a-tablet) products, and loosely compressed beads encased in tablets to optimize dosing, therapeutic, and plasma release profiles to meet patient needs in a high quality, one step manufacturing process.

To find out more about Catalent’s OSDrC® OptiDoseTM optimized dose delivery technology, click here.

OptiMeltTM hot melt extrusion enhances solubility of BCS Class 2/4 poorly soluble compounds to bring more products and better treatments to market. OptiMeltTM enables scientists to achieve desired efficacy, differentiate product profiles, enhance patient compliance, and optimize product performance.

To find out more about Catalent’s OptiMeltTM hot melt extrusion and solubility enhancement platform of technologies, click here.

Zydis® fast-dissolve tablets are the innovator brand in orally disintegrating tablets and offers the potential for increasing the range of prescription and consumer drug products that can be formulated as a lyophilized fast-dissolve dosage form. This proprietary technology has been applied to launch an ODT vaccine that was previously administered through subcutaneous injection. Buccal absorption, taste-masking, and patient convenience make Zydis® fast-dissolve tablets ideal for numerous therapeutic areas.

To find out more about Catalent’s Zydis® fast-dissolve lyophilized tablet technology, please click here. Throughout his 30 year career, Mr. Valazza has held various executive positions in product development and technical services with a focus on modified and controlled release solid dosage form applications. He is a recognized leader in the field of controlled release technology, having published articles in several scientific journals, and presented at numerous industry conferences. He currently leads Catalent’s Controlled Release Technologies global team, and is based at its Somerset, NJ headquarters. Mr. Valazza is a registered pharmacist in New Jersey and Kentucky, with a Bachelor’s degree in Pharmacy from Rutgers University, College of Pharmacy. He is a member of the Controlled Release Society (CRS) and American Association of Pharmaceutical Scientists (AAPS).

Mr. Valazza will also co-moderate the Soap Box session, for more details on this session, click here. To arrange a follow-up interview with Mr. Valazza, please contact Patricia McGee at media@catalent.com. For more information or to register for the conference, click here.

To learn more about Catalent’s Modified Release technologies, go to: www.catalent.com/controlled-release.

About Catalent

From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,400 people at 29 facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, visit www.catalent.com.

more products. better treatments. reliably supplied.™

OSDrC® is a registered trademark of Sanwa Kagaku Kenkyusho Co., Ltd

Zydis® is a registered trademark of Catalent Pharma Solutions, Inc.

OptiDoseTM and OptiMeltTM are trademarks of Catalent Pharma Solutions, Inc.

Catalent Media Contact:

Patricia McGee

+1-732-537-6407

Patricia.mcgee@catalent.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES